The FDA’s October 26, 2026 Talzenna approval expands the use of Pfizer’s drug with enzalutamide, marketed as Xtandi, to adults with a genetically defined form of metastatic prostate cancer. The decision covers metastatic androgen pathway modulation-naïve or -sensitive disease with homologous recombination repair gene mutations detected by an FDA-authorized test.

Key Takeaways

  • The FDA has approved the expanded indication; it is not a proposal or a pending U.S. application.
  • The supporting TALAPRO-3 trial enrolled 599 patients and showed improved radiographic progression-free survival.
  • Australian and Canadian regulatory reviews remain ongoing.

Talzenna approval defines a specific eligible group

The FDA’s approval of the Talzenna–enzalutamide combination adds an indication for patients whose metastatic prostate cancer is androgen pathway modulation-naïve or -sensitive and carries qualifying homologous recombination repair, or HRR, mutations. The authorization is not a blanket approval for all metastatic prostate cancer.

Eligibility requires mutation detection using an FDA-authorized test. The agency said it had previously approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostic devices to identify patients with relevant HRR gene alterations. The supplied announcement does not detail the combination’s earlier treatment indication.

TALAPRO-3 showed longer disease control

The randomized, double-blind Phase 3 trial assigned 599 patients to enzalutamide with either talazoparib, the active ingredient in Talzenna, or placebo. All patients also received continuous androgen deprivation therapy.

Median radiographic progression-free survival was not reached in the talazoparib group, compared with 45.8 months in the placebo group. The hazard ratio was 0.48, with a 95% confidence interval of 0.36–0.65, indicating a lower relative hazard of radiographic progression or death during follow-up.

That endpoint measures disease progression assessed through imaging or death; it does not by itself establish an overall survival benefit. Overall survival was an additional trial endpoint, but the supplied FDA announcement provides no result for it.

Safety requirements and international reviews

The recommended talazoparib dose is 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity. Patients must also receive a gonadotropin-releasing hormone analog or have previously undergone bilateral orchiectomy.

The prescribing information includes warnings for myelodysplastic syndrome or acute myeloid leukemia, myelosuppression and embryo-fetal toxicity. The FDA conducted the review under Project Orbis, collaborating with Australia’s Therapeutic Goods Administration and Health Canada; those agencies’ application reviews remain ongoing.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.